Accelerate Dx Lands CE Mark for ID/AST System, Initiates Clinical Trial Enrollment | GenomeWeb

NEW YORK (GenomeWeb) – Accelerate Diagnostics today announced it has received the CE-IVD mark for its Accelerate ID/AST System and ID/AST Blood Culture Assay and has begun enrolling trial sites for a preclinical study.

The Accelerate platform uses proprietary single-cell microbiology analysis technology to rapidly identify pathogens and provide information on their antibiotic susceptibility for clinical diagnosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.